Portland initiates registration in China
03 February, 2006 by Helen SchullerPortland Orthopaedics (ASX:PLD) has initiated registration of its complete range of orthopaedic products with the State Drug Administration of China (SFDA), in a process expected to take 12 months.
Prana says study validates efficacy of Alzheimer's drug
03 February, 2006 by Graeme O'NeillMelbourne Alzheimer's disease (AD) drug developer Prana Biotechnology (ASX:PBT, Nasdaq:PRAN) now has visual confirmation of its prototype plaque-buster, clioquinol, at work in an animal brain.
Ambri tech development dropped by US partner
02 February, 2006 by Helen SchullerBiosensor Enterprises (BEL) will no longer work to develop Sydney-based Ambri's (ASX:ABI) ion-channel switch (ICS), and will instead focus on out-licensing the technology.
In brief: Narhex, Norwood Abbey, Anadis, Phylogica
02 February, 2006 by Staff WritersNarhex Life Sciences (ASX:NLS) has signed a manufacturing contract with Indian, Nasdaq-listed company Dr Reddy's for initial GMP-grade production of the prodrug of Narhex's candidate HIV protease inhibitor, DG35.
Genepharm cheers regulatory approval
02 February, 2006 by Helen SchullerGeneric medicines company Genepharm Australasia's (ASX:GAA) brand of Simvastatin has been listed in the Australian Register of Therapeutic Goods, the final stage of TGA approval and registration process for its cholesterol-reducing drug.
Chemeq boosts manufacturing capacity
01 February, 2006 by Ruth BeranChemeq (ASX:CMQ) has upped the production capability of its Rockingham manufacturing facility, announcing today that it can now produce as much as 280,000 litres of the company's polymeric antimicrobial each year.
Road clear for Neuren phase III trials
01 February, 2006 by Helen SchullerThe US FDA has given the all-clear for Auckland biopharma Neuren Pharmaceuticals (ASX:NEU) to move straight into a phase III major efficacy trial for lead molecule Glypromate.
Norwood in Greek eyecare partnership
01 February, 2006 by Helen SchullerNorwood Abbey's (ASX:NAL) Norwood Eyecare division is to partner with the University of Crete, in Greece, on R&D in the field of Epi-LASIK refractive surgery and related innovations.
Imugene gets OGTR tick for poultry booster
01 February, 2006 by Graeme O'NeillLivestock vaccine developer Imugene's (ASX:IMU) chicken immune-system booster has crossed a major intersection on the road to market by receiving approval from the Office of the Gene Technology Regulator to trial its genetically modified product outside full laboratory containment.
Metabolic says obesity drug has potential in osteoporosis
01 February, 2006 by Ruth BeranMetabolic Pharmaceuticals' (ASX:MBP) obesity drug AOD9604 could potentially have a new indication for use in osteoporosis, the company has claimed.
Ventracor implants fifth heart device in US
31 January, 2006 by Helen SchullerArtificial heart company Ventracor (ASX:VCR) has implanted its fifth VentrAssist left ventricular assist system (LVAS) in the United States.
US deal to test Biosignal compounds in catheters
30 January, 2006 by Ruth BeranSydney-based Biosignal (ASX:BOS) and the Institute for Eye Research have established a collaboration with a US-based medical device company to test Biosignal's anti-biofilm compounds coated on catheters.
AtCor Medical boasts sales, revenue growth
30 January, 2006 by Helen SchullerAtCor Medical (ASX:ACG), the developer and marketer of SphygmoCor, a system to measure central cardiovascular function non-invasively, today announced sales of $1.73 million for the six months to 31 December 2005, up 40 per cent compared to the previous corresponding period
Russia recommends approval of Solagran liver disease drug
27 January, 2006 by Helen SchullerThe Russian Ministry of Health has recommended the approval of Melbourne-based Solagran's (ASX:SLA) Ropren, the finished form of Bioeffective R, as a treatment for chronic liver disease.
Mimotopes and Genzyme Pharmaceuticals to collaborate
27 January, 2006 by Ruth BeranPharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases.
